SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: StockDoc who wrote (14066)7/11/2000 12:41:45 PM
From: Cacaito  Read Replies (1) | Respond to of 17367
 
""Tuesday, July 11, 2000, Xoma soars on initiation
--10:49 am - By Michael Baron
Xoma Ltd. (XOMA: news, msgs) is getting a huge lift from US Bancorp Piper Jaffray's decision to initiate coverage of the Berkley, Calif., biopharmaceutical firm with a "strong buy" rating and a two-year price target of $14 a share. Xoma is topping the percentage gainers on the Nasdaq, adding 1 7/16, or 33.8 percent, to 5 11/16 on heavy volume of 3 million shares. Average daily volume is 1.37 million shares. US Bancorp Piper Jaffray also started coverage of a number of other companies in the healthcare sector. In addition to Xoma, analyst Mark Augustine initiated coverage of Immunex (IMNX: news, msgs) with a "buy" rating and Genentech (DNA: news, msgs) with a "strong buy" rating. Analyst Cynthia Glass also made a number of calls. She started coverage of Mylan Laboratories (MYL: news, msgs) with a "neutral" rating, Jones Pharmaceuticals (JEMD: news, msgs) with a "buy" rating, Forest Laboratories (FRX: news, msgs) with a "strong buy" rating, Andrx Corp. (ADRX: news, msgs) with a "strong buy" rating, and Barr Laboratories (BRL: news, msgs) with a "buy" rating.""

The reason for the season! Now, there is a nice exit point here! This seems to be the exit point for the last chunk of shares offered at $5.5, with USBPiperjaffray leading for Sutro! How they could do it is just plain amazing! Nice Job.